The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 04, 2022

Filed:

Dec. 14, 2020
Applicant:

The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US);

Inventors:

Roy Louis Maute, San Francisco, CA (US);

Kipp Andrew Weiskopf, Brookline, MA (US);

Aaron Michael Ring, New Haven, CT (US);

Irving L. Weissman, Stanford, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 45/06 (2006.01); A61B 17/00 (2006.01); A61L 31/14 (2006.01); A61M 25/10 (2013.01); A61F 2/945 (2013.01); A61K 38/17 (2006.01); A61F 2/82 (2013.01); A61F 2/04 (2013.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2833 (2013.01); A61B 17/00491 (2013.01); A61F 2/945 (2013.01); A61K 38/1774 (2013.01); A61K 45/06 (2013.01); A61L 31/145 (2013.01); A61M 25/104 (2013.01); C07K 16/2803 (2013.01); C07K 16/2863 (2013.01); A61B 2017/00654 (2013.01); A61B 2017/00893 (2013.01); A61B 2017/00898 (2013.01); A61F 2/82 (2013.01); A61F 2002/041 (2013.01); A61F 2002/044 (2013.01); A61F 2002/045 (2013.01); A61F 2002/048 (2013.01); A61F 2002/823 (2013.01); A61F 2210/0085 (2013.01); A61F 2250/0067 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61M 2025/105 (2013.01); C07K 2317/24 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01);
Abstract

Methods and compositions are provided for inducing phagocytosis of a target cell, treating an individual having cancer, treating an individual having an intracellular pathogen infection (e.g., a chronic infection), and/or reducing the number of inflicted cells (e.g., cancer cells, cells infected with an intracellular pathogen, etc.) in an individual. Methods and compositions are also provided for predicting whether an individual is resistant (or susceptible) to treatment with an anti-CD47/SIRPA agent. In some cases, the subject methods and compositions include an anti-MHC Class I/LILRB1 agent. In some cases, the subject methods and compositions include an anti-MHC Class I/LILRB1 agent and an anti-CD47/SIRPA agent (e.g., co-administration of an anti-MHC Class I/LILRB1 agent and an anti-CD47/SIRPA agent). Kits are also provided for practicing the methods of the disclosure.


Find Patent Forward Citations

Loading…